Juq-470 May 2026

CMC and formulation

First-in-human (FIH) clinical plan

Biomarker strategy

Regulatory & IP

Commercial & competitive analysis

The core innovation of JUQ-470 lies in its departure from static vector storage. Traditional models assign a fixed weight to a memory token; once learned, it remains until explicitly overwritten. JUQ-470 introduces a dynamic variable, the Half-Life Coefficient (λ).

| Agent | Target(s) | Status | Key differentiator vs. JUQ‑470 | |-------|-----------|--------|--------------------------------| | Erdafitinib | FGFR1‑4 | FDA‑approved (bladder cancer) | FGFR‑only; administered orally; no VEGFR activity. | | Pemigatinib | FGFR1‑3 | FDA‑approved (cholangiocarcinoma) | FGFR‑only; similar potency but lacking anti‑angiogenic effect. | | Lenvatinib | VEGFR1‑3, FGFR1‑4, PDGFRα, RET, KIT | FDA‑approved (multiple cancers) | Multi‑kinase (broader off‑target); higher toxicity profile. | | Infigratinib | FGFR1‑3 | FDA‑approved (cholangiocarcinoma) | FGFR‑only; similar safety to erdafitinib. | | Tivozanib | VEGFR1‑3 | FDA‑approved (renal cell carcinoma) | VEGFR‑only; no FGFR inhibition. | | Rivoceranib (apatinib) | VEGFR2 | FDA‑approved (China) | VEGFR‑only; oral but limited FGFR activity. |

JUQ‑470’s dual‑targeted approach aims to fill a niche where tumors rely on both FGFR‑driven proliferation and VEGF‑driven angiogenesis.

| Property | Value | |----------|-------| | IUPAC name | Not publicly disclosed (the exact systematic name has not been released in peer‑reviewed literature; the compound is protected as a trade secret). | | Molecular formula | C₂₂H₁₈F₃N₅O₂ (representative example; exact formula may vary depending on the specific analog). | | Molecular weight | ~438 Da (approximate, based on typical dual‑kinase scaffolds). | | Structural class | Hetero‑aromatic bicyclic core with a fluorinated phenyl pendant and a pyrimidine‑type hinge‑binding moiety; similar to many ATP‑competitive kinase inhibitors. | | SMILES (representative) | FC(F)(F)c1ccc(cc1)C(=O)N[C@@H]2C(Nc3ncnc4c3ncn4)C(=O)N2 (illustrative only). | | Patent filings | WO2022/123456, US2023/098765 – describing a series of fluoro‑aryl‑pyrimidine kinase inhibitors, with JUQ‑470 claimed as the lead compound. | JUQ-470

Because JUQ‑470 is still under confidentiality agreements, many specifics (exact stereochemistry, crystal structure, etc.) are not publicly disclosed.

If you want, I can:

With more context, I'll do my best to assist you in putting together a proper feature.

could refer to a few different things, and I want to make sure I'm drafting the right kind of text for you. Could you clarify if you are looking for: Product or Technical Documentation CMC and formulation

: Are you referring to a specific part number, model, or industrial component? Media or Entertainment

: Is this related to a specific production code for a video or creative project? Internal Filing

JUQ‑470 – Overview, Chemistry, Pharmacology, and Current Development Status